Citadel Advisors
WX

Citadel Advisors’s WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS WX Stock Holding History

Citadel Advisors’s Portfolio WX Stock Details WX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-37,746
Closed -$1.63M – 9665
2015
Q3 		$1.63M Sell
37,746
-323,456
-90% -$13.6M ﹤0.01% 3204
2015
Q2 		$15.3M Buy
361,202
+297,147
+464% +$12.5M 0.01% 1191
2015
Q1 		$2.48M Buy
64,055
+29,103
+83% +$1.12M ﹤0.01% 2800
2014
Q4 		$1.18M Sell
34,952
-49,464
-59% -$1.75M ﹤0.01% 3565
2014
Q3 		$2.96M Buy
84,416
+61,174
+263% +$2.1M ﹤0.01% 2472
2014
Q2 		$764K Buy
+23,242
New +$795K ﹤0.01% 3842
2014
Q1 		– Sell
-12,775
Closed -$491K – 8205
2013
Q4 		$491K Buy
12,775
+1,960
+18% +$61.9K ﹤0.01% 4045
2013
Q3 		$296K Buy
+10,815
New +$256K ﹤0.01% 4364

Other funds holding WX

Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return
CCS
Crosspoint Capital Strategies Orinda, California $50.4M AUM 15.37% 1-Year Est. Return

Citadel Advisors's WX Position: Q4 2015 in Review

Citadel Advisors sold out of WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS (WX) in Q4 2015, closing a stake of 37,746 shares — an estimated $1.63M sold.

Citadel Advisors first reported a position in WX in Q3 2013 and held it in 8 quarters. The position peaked at $15.3M in Q2 2015. 2 funds tracked by Wall St. Rank hold WX as of Q4 2015.

  • Citadel Advisors reported no remaining WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position as of Q4 2015 after selling out during the quarter.
  • Citadel Advisors sold 37,746 WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS shares in Q4 2015, an estimated $1.63M.
  • Citadel Advisors first reported a position in WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS in Q3 2013 and held it in 8 quarters.
  • Citadel Advisors's WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS position peaked at $15.3M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held WUXI PHARMATECH, CAYMAN INC REPSTG 8 ORD SHS as of Q4 2015.

Based on Citadel Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.